CN107496908A - Application of the irisin in anti-inflammatory drug is prepared - Google Patents
Application of the irisin in anti-inflammatory drug is prepared Download PDFInfo
- Publication number
- CN107496908A CN107496908A CN201710785547.0A CN201710785547A CN107496908A CN 107496908 A CN107496908 A CN 107496908A CN 201710785547 A CN201710785547 A CN 201710785547A CN 107496908 A CN107496908 A CN 107496908A
- Authority
- CN
- China
- Prior art keywords
- irisin
- inflammatory
- inflammation
- apply according
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides application of the irisin in anti-inflammatory drug is prepared, and belongs to pharmaceutical technology field, and the irisin has the amino acid sequence as shown in SEQ ID NO.1 in sequence table.Irisin is applied in the preparation of anti-inflammatory medicaments by the present invention, and irisin has obvious antiinflammatory action.Experiment shows, effectively can mitigate or suppress the occurrence and development of inflammation in 12~24h.Meanwhile the present invention provides a new intervention target spot to prepare anti-inflammatory drug, irisin is applied in anti-inflammatory drug exploitation, to prepare the method for preferably treatment diseases associated with inflammation medicine.The present invention provides brand-new selection and Research idea for anti-inflammatory drug, while has widened application of the irisin in field of medicaments.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to application of the irisin in anti-inflammatory drug is prepared.
Background technology
Inflammation is exactly usually " inflammation " described in people, is a kind of defense reaction of the body for stimulation, show as it is red,
Swollen, heat, pain and dysfunction.The factor of tissue and cellular damage can be caused to cause inflammation.Although inflammation is basic
Defense reaction, but in pathological conditions, often result in serious injuries of tissues and organs, or even threat to life.Inflammation is in a variety of diseases
Played an important role during occurrence and development, effectively control inflammation and very crucial work is played in the preventing and treating of some diseases associated with inflammation
With.
At present, for inflammation treatment usually using antibiotic, but antibiotic is only effective to infective inflammation, and to non-
Infective inflammation is invalid.In addition, though existing glucocorticoid medicine and non-steroid anti-inflammatory drug can be used for anti-inflammatory treatment,
But the effect of reaching expected anti-inflammatory, it is necessary to take the anti-inflammatory drug, and largely take such for a long time in large quantities for a long time
Anti-inflammatory drug can produce adverse reaction, and side effect is big, and larger pain is brought to patient.
Irisin (Irisin) is a kind of muscle factor found in 2012, is that type III fibronectin component includes albumen 5
What is formed after (fibronectintype III domain-containingprotein 5, FNDC5) proteolysis secretes
Polypeptide fragment, it is signaling molecule existing for body physiological state, can promotes the white adipocyte of mouse that brown cell occurs
Sample changes.
The content of the invention
In view of this, the application it is an object of the invention to provide irisin in anti-inflammatory drug is prepared, the medicine tool
There is obvious antiinflammatory action.
In order to realize foregoing invention purpose, the present invention provides following technical scheme：
The invention provides application of the irisin (Irisin) in anti-inflammatory medicaments are prepared, the irisin has such as sequence
Amino acid sequence in list shown in SEQ ID NO.1.
Preferably, the formulation of the medicine is injection, externally-applied ointment or external suppository.
Preferably, the mass concentration of irisin is 2mg/mL~10mg/mL in the injection；The externally-applied ointment is outer
It is 1~5mg/g with the mass concentration of irisin in suppository.
Preferably, the injection includes irisin and water for injection；Using irisin as effectively in the externally-applied ointment
Composition, using glycerin monostearate and purified water as auxiliary material；The external suppository is using irisin as active ingredient, to mix fat
Acid glyceride and purified water are auxiliary material.
Preferably, the inflammation is caused by lipopolysaccharides (LPS).
Preferably, the irisin reaches the work of anti-inflammatory by suppressing the expression of inflammatory factor in macrophage
With；The inflammatory factor includes IL-1 β, TNF-α, IL-6, IL-8 and Nos2.
Preferably, the irisin by suppress in macrophage the phosphorylation of NF- κ B-p65 molecules or p38 molecules so as to
Have the function that anti-inflammatory.
Preferably, the inflammation is as caused by Angiotensin II.
Preferably, the irisin is to reach anti-inflammatory by suppressing the expression of IL- β in vascular smooth muscle cells
Effect.
Preferably, the irisin reduces inflammatory factor expression and inflammatory cell leaching in adipose tissue inflammation caused by obesity
Profit；The inflammatory cell is macrophage；The inflammatory factor is TNF-α or IL-1 β.
The invention provides application of the irisin in anti-inflammatory medicaments are prepared, the irisin has as in sequence table
Amino acid sequence shown in SEQ ID NO.1.Irisin is applied in the preparation of anti-inflammatory medicaments by the present invention, and irisin has
Obvious antiinflammatory action.Experiment shows, effectively can mitigate or suppress the occurrence and development of inflammation in 12~24h.Meanwhile this
Invent and provide a new intervention target spot to prepare anti-inflammatory drug, irisin is applied in anti-inflammatory drug exploitation, to prepare more
The method of good treatment diseases associated with inflammation medicine.The present invention provides brand-new selection and Research idea for anti-inflammatory drug, simultaneously
Application of the irisin in field of medicaments is widened.
Further, application of the irisin provided by the invention in anti-inflammatory medicaments are prepared, further discloses iris
The mechanism of the anti-inflammatory of element, mainly by suppressing expression and the inflammatory signals path key signal molecule NF- κ B- of inflammatory factor
P65 and p38 activation reaches the purpose of anti-inflammatory.
Brief description of the drawings
Fig. 1 is that Irisin suppresses the table of Turnover of Mouse Peritoneal Macrophages M1 polarization and inflammatory factor caused by LPS in embodiment 1
Reach；
Fig. 2 is the activation that Irisin suppresses the NF- κ B-p65 of Turnover of Mouse Peritoneal Macrophages caused by LPS in embodiment 2；
Fig. 3 is the p38 activation that Irisin suppresses Turnover of Mouse Peritoneal Macrophages caused by LPS in embodiment 3；
Fig. 4 is the inflammatory factor that Irisin suppresses Mouse Vascular Smooth Muscle Cell inflammation caused by Ang II in embodiment 4
IL- β are expressed
Fig. 5 is the inflammatory cell leaching that Irisin reduces adipose tissues inflammation caused by high fat diet in embodiment 5
Profit；
Fig. 6 is the inflammatory factor that Irisin reduces adipose tissues inflammation caused by high fat diet in embodiment 6
Expression.
Embodiment
The invention provides application of the irisin in anti-inflammatory medicaments are prepared, the irisin has as in sequence table
Amino acid sequence shown in SEQ ID NO.1.
In the present invention, the source of the irisin is not particularly limited, using iris well-known to those skilled in the art
Element.In the embodiment of the present invention, the irisin is bought from Phoenix Pharmaceuticals companies of the U.S..
In the present invention, the formulation of the medicine is preferably injection, externally-applied ointment or external suppository.
In the present invention, the injection preferably includes irisin and water for injection.In the present invention, iris in the injection
The mass concentration of element is preferably 2~10mg/mL, more preferably 4~8mg/mL, most preferably 5mg/mL.The system of the injection
Preparation Method is not particularly limited, using injection preparation method well-known to those skilled in the art.The injection
Application method is to be subcutaneously injected.
In the present invention, the externally-applied ointment includes irisin and auxiliary material.The mass concentration of irisin in the externally-applied ointment
Preferably 1~5mg/g, more preferably 2~4mg/g, most preferably 3mg/g.The auxiliary material includes glycerin monostearate and pure
Change water.Mass concentration of the glycerin monostearate in externally-applied ointment is preferably 5~15g, more preferably 10g.It is described outer
It is not particularly limited with the preparation method of ointment, using externally-applied ointment preparation method well-known to those skilled in the art.
The application method of the externally-applied ointment is to be coated in the skin and mucosa or wound location of inflammation.
In the present invention, the external suppository includes irisin and auxiliary material.The mass concentration of irisin in the external suppository
Preferably 1~5mg/g, more preferably 2~4mg/g, most preferably 3mg/g.The auxiliary material includes glycerol and purified water.
Mass concentration of the glycerol in external suppository is preferably 1~3g, more preferably 2g.The preparation of the external suppository
Method is not particularly limited, using the method well-known to those skilled in the art for preparing external suppository.The external application bolt
The application method of agent is used as pessary.
In the present invention, the injection times for spraying of the medicine is preferably 1~2 times/day, every time preferably 0.5~2mL,
Most preferably 1mL.Externally-applied ointment times for spraying is preferably 2~6 times/day, every time 0.5~2g.External suppository times for spraying is preferred
For 1 times/day, 1 every time.
In the present invention, the inflammation is as caused by lipopolysaccharides.The irisin is preferably by suppressing scorching in macrophage
The expression of inflammation factor is so as to having the function that anti-inflammatory；The inflammatory factor preferably include IL-1 β, TNF-α, IL-6, IL-8 and
Nos2.The irisin is preferably by suppressing the phosphorylation and inflammatory cell of NF- κ B-p65 molecules or p38 molecules in macrophage
Infiltrate so as to have the function that anti-inflammatory.
In the present invention, the inflammation is as caused by Angiotensin II.The irisin is preferably put down by suppressing blood vessel
IL- β expression is so as to having the function that anti-inflammatory in sliding myocyte.
In the present invention, the Irisin reduces inflammatory factor in adipose tissue inflammation caused by obesity and expressed；The inflammatory
The factor is TNF-α or IL-1 β.
In the present invention, the Irisin reduces inflammatory cell in adipose tissue caused by obesity and expressed；The inflammatory cell is huge
Phagocyte.
Application of the irisin provided by the invention in anti-inflammatory drug is prepared is carried out specifically with reference to embodiment
It is bright, but they can not be interpreted as limiting the scope of the present invention.
Embodiment 1
The preparation process of Turnover of Mouse Peritoneal Macrophages
Experiment uses 6 week old male C57/BL6 mouse, and 4% coloured glaze base glycollate 2ml is injected intraperitoneally, and is taken off after 4 days at cervical approach
Dead mouse, and soak 2min in 75% alcohol.Open abdominal cavity under sterile making, with 5ml disposable syringes suction 3~
DMEM nutrient solution injection abdominal cavities of the 4ml containing 3% hyclone, is massaged whole abdominal cavity with sterile swab stick and contains macrophage to obtain
The nutrient solution of cell, by medium centrifugal 10min (200g), plate is planted after resuspension processing, the debris for rinsing out floating after 6~8h
And liquid is changed, adherent is the peritoneal macrophage obtained.
Drug-treated method：The peritoneal macrophage of culture gives the pretreatment of 20nM Irisin solution, per ml nutrient solutions
(about 1 × 106Individual cell) add 20pmol the μ l of irisin 1.100 μ g/mL μ l of LPS 1 are given after 2h to induce M1 to polarize
Expressed with inflammatory factor, mRNA level in-site is determined after 12h, Irisin solution is replaced as control 1 using PBS solution, with small caused by LPS
Mouse peritoneal macrophage M1 polarization cells are control 2.
MRNA level in-site assay method is as follows：
1. extract total serum IgE：Every 1 × 106Cell in add 1ml RNAiso Plus reagents, after being stored at room temperature 5min,
0.2ml chloroforms are added, acutely shake 30S, it is obvious to being layered to be stored at room temperature 5min., will after centrifuging (4 DEG C) 15min through 12,000g
Upper strata aqueous phase is transferred in new 1.5ml centrifuge tube, is added 0.5ml isopropanols, after fully mixing, is stored at room temperature 15min, then
After 12,000g centrifuges (4 DEG C) 15min.Supernatant discarding and 75% ethanol for adding 1ml, (4 are centrifuged after mixing by 7500g
℃)5min.5~10min of room temperature or vacuum drying after supernatant discarding, add the 20 μ l ddH without RNase2Carried out after O dissolvings
RNA is quantified and purity analysis.
2. reverse transcription is carried out with PrimeScript reverse transcription reagent box to obtain cDNA.
3. cDNA dye methods and SYBR amplification kits are detected into relative mRNA level in-site.
As a result it is as shown in Figure 1.Data are represented with mean ± standard error.*P<0.05vs.PBS；P<0.05vs.LPS.n=
3.Wherein, inflammatory factor IL-1 β, TNF-α, IL-6, IL-8 and Nos2 are the marks of macrophage M1 polarization.
The M1 types polarization of macrophage is the important symbol in inflammation occurrence and development, and as shown in Figure 1, irisin suppresses LPS
The polarization of M1 types and the expression of inflammatory factor of caused macrophage, this shows that irisin has obvious antiinflammatory action.
Embodiment 2
Westernblotting methods measure phosphorylated protein is horizontal
Turnover of Mouse Peritoneal Macrophages prepared by embodiment 1, the pretreatment of irisin solution is given, per ml nutrient solutions (about 1 ×
106Individual cell) add 20pmol the μ l of irisin 1.LPS (100ng/mL) is given after pretreatment 2h, then adds and contains by 0.5h
The RIPA lysates of inhibitors of phosphatases are to extract the albumen of cell, after the completion of determination of protein concentration, by every μ g of hole 50 loading
Amount, which adds electrophoresis 1.5h in polyacrylamide gel, makes Protein Separation.After gel electrophoresis terminates, by gel, filter paper and pvdf membrane group
Wet turn " sandwich " is filled, is put into transferring film groove, constant voltage 100V is set, shifts 1h.To displaced the pvdf membrane of albumen containing
There is room temperature in the TBST buffer solutions of 5% skimmed milk power to close 2h；With TBST buffer solutions dilution primary antibody (Ser468-
Phosphorylated p65,1:1000) film 10min × 3 time are washed after 4 DEG C of overnight incubations, adds the peppery of TBST buffers
Root peroxidase conjugate IgG (1：5000, goat-anti rabbit) incubation at room temperature 1h；TBST buffer solutions are exposed after washing film 10min × 3 time
Light.The relative expression quantity of phosphorylated protein is the ratio between optical density of phosphorylated p65 and p65 total proteins.It is molten with PBS
Liquid replaces Irisin solution as control 1, and cell is polarized as control 2 using Turnover of Mouse Peritoneal Macrophages M1 caused by LPS.
Fig. 2 is the activation that Irisin suppresses the NF- κ B-p65 of Turnover of Mouse Peritoneal Macrophages caused by LPS.Data are with mean
± standard error represents.*P<0.05vs.PBS；P<0.05vs.LPS.n=3.
NF- κ B-p65 phosphorylations are the important symbol things of inflammatory signals Pathway Activation.As shown in Figure 2, Irisin can be obvious
Suppress the phosphorylation of the NF- κ B-p65 of Turnover of Mouse Peritoneal Macrophages caused by LPS, so as to suppress inflammatory signals Pathway Activation, suppression
The further development of inflammation processed.
Embodiment 3
Western blotting methods measure phosphorylated protein is horizontal
Turnover of Mouse Peritoneal Macrophages prepared by embodiment 1 gives irisin (20nM) pretreatments, per ml nutrient solutions (about 1 ×
106Individual cell) add 20pmol the μ l of irisin 1.LPS (100ng/mL) is given after pretreatment 2h, then adds and contains by 0.5h
The RIPA lysates of inhibitors of phosphatases are to extract the albumen of cell, after the completion of determination of protein concentration, by every μ g of hole 50 loading
Amount, which adds electrophoresis 1.5h in polyacrylamide gel, makes Protein Separation.After gel electrophoresis terminates, by gel, filter paper and pvdf membrane group
Wet turn " sandwich " is filled, is put into transferring film groove, constant voltage 100V is set, shifts 1h.To displaced the pvdf membrane of albumen containing
There is room temperature in the TBST buffer solutions of 5% skimmed milk power to close 2h；With TBST buffer solutions dilution primary antibody (Thr180-
Phosphorylated p38,1:1000) film 10min × 3 time are washed after 4 DEG C of overnight incubations, adds the peppery of TBST buffers
Root peroxidase conjugate IgG (1：5000, goat-anti rabbit) incubation at room temperature 1h；TBST buffer solutions are exposed after washing film 10min × 3 time
Light.The relative expression quantity of phosphorylated protein is the ratio between optical density of phosphorylated p38 and p38 total proteins.It is molten with PBS
Liquid replaces Irisin solution as control 1, and cell is polarized as control 2 using Turnover of Mouse Peritoneal Macrophages M1 caused by LPS.
As a result as shown in figure 3, data are represented with mean ± standard error, * P<0.05vs.PBS；P<0.05vs.LPS.n=
3.From the figure 3, it may be seen that Irisin significantly inhibits p38 phosphorylations caused by Turnover of Mouse Peritoneal Macrophages application LPS.P38 phosphorylations are
The important symbol thing of inflammatory signals Pathway Activation.Irisin suppresses the activation of inflammatory signals path by suppressing p38 phosphorylations,
And then the purpose of anti-inflammatory.
Embodiment 4
Using the primary smooth muscle cells of enzyme digestion separating mouse aorta pectoralis, VSMCs cultures containing 10%FBS,
100U/ml penicillin, 100mg/ml streptomysins DMEM culture mediums in, be placed in 37 DEG C, 5% CO2And carried out under saturated humidity
Culture, liquid is changed once every 3~4d, and when cell culture to 80% is after converging, 0.25% pancreatin digests 1:4 carry out passage training
Support.Test the primary VSMCs to the 6th generation using 2nd generation.
The VSMCs of culture gives (1 μM) pretreatment of Ang II, gives irisin (20nM) after 0.5h, i.e., per ml nutrient solutions
(about 1 × 106Individual cell) add 20pmol the μ l of irisin 1.Used again by 12h in embodiment 3
Westernblotting methods determine IL- β protein expression levels.Irisin solution is replaced as control using PBS solution.
As a result as shown in figure 4, data are represented with mean ± standard error.*P<0.05vs.Ctrl；P<0.05vs.PBS.n=
3.As shown in Figure 4, compared with the control, Irisin suppresses the inflammatory factor IL- β of Mouse Vascular Smooth Muscle Cell caused by Ang II
Expression, this shows that irisin can effectively suppress the inflammation of VSMCs caused by Ang II.
Embodiment 5
It is prepared by adipose tissues inflammatory model：The male C57/BL6 mouse of 6 week old are randomly divided into standard feed group
(Ctrl groups, fat provides 12% heat in diet) and high fat diet group (HFD groups, the heat of fat offer 60% in diet
Amount), raise 20 weeks altogether.
Miniosmotic pump (model is used after 20 weeks：1002, Alzet companies, the U.S.) subcutaneously persistently give irisin
(0.24nmol/ μ l, 1.44nmol/day, continuing 2 weeks, μ l of irisin 100 are filled in miniosmotic pump), takes adipose tissue to enter after 2 weeks
Row F4/80 immunohistochemical studies.F4/80 is the surface marker of macrophage, and macrophage is important inflammatory cell, passes through fat
Cell infiltration degree can be evaluated in the F4/80 SABCs of fat tissue.
SABC step：The adipose tissue of mouse is prepared into paraffin section, successively by section be put into the 15min of dimethylbenzene I,
The 15min of dimethylbenzene II, the 5min of absolute ethyl alcohol I, the 5min of absolute ethyl alcohol II, 85% alcohol 5min and 75% alcohol 5min, distilled water
Section is put into lucifuge in 3% hydrogenperoxide steam generator room temperature and is incubated 25min after washing, and washs 3 times, reaches blocking Endogenous peroxide
The purpose of enzyme.3%BSA uniform fold tissues, room temperature closing 30min is added dropwise in section after slightly drying.Confining liquid is gently got rid of, is being cut
On piece be added dropwise PBS prepare primary antibody (anti-F4/80 antibody, 1：100), section lies against 4 DEG C of overnight incubations in wet box.Second day will
Corresponding to primary antibody kind is added dropwise in slide secondary antibody (HRP marks) after washing 3 times covers tissue, incubation at room temperature 50min, and scrubbed 3
DAB nitrite ions are added dropwise after secondary, developing time is controlled under microscope, the positive is brown color, and running water rinses section color development stopping.Soviet Union
Lignin redyes 3min, and section is sequentially placed into 75% alcohol 6min, 85% alcohol 6min, the 6min of absolute ethyl alcohol I, absolute ethyl alcohol II
Transparent, neutral gum mounting is dehydrated in 6min and the 5min of dimethylbenzene I.ImmunohistochemistryResults Results are evaluated under microscope：Bush uniformly dyeing is thin
Karyon is blueness, and the positive expression that DAB shows is brown color.
As a result as shown in figure 5, data are represented with mean ± standard error, * P<0.05vs.Ctrl；P<0.05vs.PBS.n=
6.F4/80 is the surface marker of macrophage, and macrophages infiltration journey can be evaluated by the F4/80 SABCs of adipose tissue
Degree.
As shown in Figure 5, the cell infiltration caused by irisin reductions obesity during adipose tissue inflammation, cell infiltration are
The characteristic features of inflammation, this shows that irisin can effectively suppress adipose tissue inflammation.
Embodiment 6
It is prepared by Mice model of obesity：The male C57/BL6 mouse of 6 week old are randomly divided into standard feed group (Ctrl groups, diet
Middle fat provides 12% heat) and high fat diet group (HFD groups, fat provides 60% heat in diet), raising 20 weeks altogether.
Miniosmotic pump (model is used after 20 weeks：1002, Alzet companies, the U.S.) subcutaneously persistently give irisin
(0.24nmol/ μ l, 1.44nmol/day, continuing 2 weeks, μ l of irisin 100 are filled in miniosmotic pump), takes adipose tissue to survey after 2 weeks
Determine inflammatory factor TNF-α and IL-1 β mRNA expressions.Using PBS solution treatment group as control.
MRNA level in-site assay method：
1. extract total serum IgE：1ml RNAiso Plus reagents are added in per 50mg adipose tissues, after being stored at room temperature 5min,
0.2ml chloroforms are added, acutely shake 30sec, it is obvious to being layered to be stored at room temperature 5min.After (4 DEG C) 15min being centrifuged through 12,000g,
Upper strata aqueous phase is transferred in new 1.5ml centrifuge tube, adds 0.5ml isopropanols, after fully mixing, be stored at room temperature 15min,
Again after 12,000g centrifuges (4 DEG C) 15min.Supernatant discarding and 75% ethanol for adding 1ml, (4 are centrifuged after mixing by 7500g
℃)5min.Room temperature or vacuum drying 5-10min after supernatant discarding, add the 20 μ l ddH without RNase2RNA is carried out after O dissolvings
Quantitative and purity analysis.
2. reverse transcription is carried out with PrimeScript reverse transcription reagent box to obtain cDNA.
3. cDNA dye methods and SYBR amplification kits are detected into relative mRNA level in-site.
As a result as shown in fig. 6, data are represented with mean ± standard error.*P<0.05vs.Ctrl；P<0.05vs.PBS.n=
6.It will be appreciated from fig. 6 that Irisin can effectively reduce the inflammatory factor expression in adipose tissues.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Sequence table
<110>Nanjing Medical University
<120>Application of the irisin in anti-inflammatory drug is prepared
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 112
<212> PRT
<213>Unknown (Unknown)
<400> 1
Asp Ser Pro Ser Ala Pro Val Asn Val Thr Val Arg His Leu Lys Ala
1 5 10 15
Asn Ser Ala Val Val Ser Trp Asp Val Leu Glu Asp Glu Val Val Ile
20 25 30
Gly Phe Ala Ile Ser Gln Gln Lys Lys Asp Val Arg Met Leu Arg Phe
35 40 45
Ile Gln Glu Val Asn Thr Thr Thr Arg Ser Cys Ala Leu Trp Asp Leu
50 55 60
Glu Glu Asp Thr Glu Tyr Ile Val His Val Gln Ala Ile Ser Ile Gln
65 70 75 80
Gly Gln Ser Pro Ala Ser Glu Pro Val Leu Phe Lys Thr Pro Arg Glu
85 90 95
Ala Glu Lys Met Ala Ser Lys Asn Lys Asp Glu Val Thr Met Lys Glu
100 105 110
Claims (10)
1. application of the irisin in anti-inflammatory medicaments are prepared, the irisin has as shown in SEQ ID NO.1 in sequence table
Amino acid sequence.
2. apply according to claim 1, it is characterised in that the formulation of the medicine is injection, externally-applied ointment or external application
Suppository.
3. apply according to claim 2, it is characterised in that in the injection mass concentration of irisin be 2mg/mL~
10mg/mL；The mass concentration of irisin is 1~5mg/g in the externally-applied ointment or external suppository.
4. apply according to claim 3, it is characterised in that the injection includes irisin and water for injection.
5. apply according to claim 1, it is characterised in that the inflammation is as caused by lipopolysaccharides.
6. apply according to claim 5, it is characterised in that the irisin is by suppressing inflammatory factor in macrophage
Expression so as to having the function that anti-inflammatory；The inflammatory factor includes IL-1 β, TNF-α, IL-6, IL-8 and Nos2.
7. apply according to claim 5, it is characterised in that the irisin is by suppressing NF- κ B-p65 in macrophage
The phosphorylation of molecule or p38 molecules is so as to having the function that anti-inflammatory.
8. apply according to claim 1, it is characterised in that the inflammation is as caused by Angiotensin II.
9. apply according to claim 8, it is characterised in that the irisin is by suppressing IL- β in vascular smooth muscle cells
Expression so as to having the function that anti-inflammatory.
10. apply according to claim 1, it is characterised in that the irisin reduces adipose tissue inflammation caused by obesity
Middle inflammatory factor expression and cell infiltration；The inflammatory factor is TNF-α and IL-1 β, and the inflammatory cell is macrophage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710785547.0A CN107496908A (en) | 2017-09-04 | 2017-09-04 | Application of the irisin in anti-inflammatory drug is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710785547.0A CN107496908A (en) | 2017-09-04 | 2017-09-04 | Application of the irisin in anti-inflammatory drug is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107496908A true CN107496908A (en) | 2017-12-22 |
Family
ID=60695768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710785547.0A Pending CN107496908A (en) | 2017-09-04 | 2017-09-04 | Application of the irisin in anti-inflammatory drug is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107496908A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108635571A (en) * | 2018-07-19 | 2018-10-12 | 西安交通大学医学院第附属医院 | Irisin（irisin）Application in preventing and treating Severe Acute Pancreatitis SAP drug |
| CN110101845A (en) * | 2019-05-24 | 2019-08-09 | 北京大学 | Application of the irisin in the drug that preparation prevention and treatment Postoperative Cognitive Dysfunction and blood-brain barrier are damaged mediated encephalopathy |
| CN110772528A (en) * | 2019-12-11 | 2020-02-11 | 吉林大学 | Application of iris polysaccharide in preparation of medicine for preventing and treating leptospirosis |
| CN110893233A (en) * | 2019-12-19 | 2020-03-20 | 川北医学院附属医院 | Application of irisin in preparation of anti-inflammatory drugs |
| CN111808186A (en) * | 2019-12-19 | 2020-10-23 | 山东大学第二医院 | Human-derived secretory FNDC5 protein and preparation method and application thereof |
| CN113692445A (en) * | 2019-04-02 | 2021-11-23 | 巴伊沃爱普有限公司 | Recombinant irisin gene for optimizing expression in plants and method for producing recombinant irisin protein by using same |
| WO2023184332A1 (en) * | 2022-03-31 | 2023-10-05 | 深圳先进技术研究院 | Ovary-targeting polypeptide and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106084038A (en) * | 2016-06-22 | 2016-11-09 | 常熟理工学院 | A kind of people recombinates the expression in Pichia sp. of the Irisin albumen and purification process |
-
2017
- 2017-09-04 CN CN201710785547.0A patent/CN107496908A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106084038A (en) * | 2016-06-22 | 2016-11-09 | 常熟理工学院 | A kind of people recombinates the expression in Pichia sp. of the Irisin albumen and purification process |
Non-Patent Citations (6)
| Title |
|---|
| A.I. MAZUR-BIALY,ET AL.: "NEW INSIGHT INTO THE DIRECT ANTI-INFLAMMATORY ACTIVITY OF A MYOKINE IRISIN AGAINST PROINFLAMMATORY ACTIVATION OF ADIPOCYTES IMPLICATION FOR EXERCISE IN OBESITY", 《JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY》 * |
| SHAO L,ET AL.，: "Irisin-mediated protective effect on LPS-induced acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells", 《BIOCHEM BIOPHYS RES COMMUN》 * |
| 杨宇峰，滕飞主编: "《代谢综合征中西医结合治疗学》", 31 May 2015, 沈阳：辽宁科学技术出版社 * |
| 王建军等: "幽门螺杆菌作用巨噬细胞后诱导的炎症反应研究", 《中国免疫学杂志》 * |
| 蒋小英等: "血管紧张素Ⅱ2 型受体对AngⅡ诱导成年大鼠心肌成纤维细胞分泌α-", 《南方医科大学学报》 * |
| 陈英编著: "《精神疾病的分子生物学与遗传研究》", 30 June 2014, 北京：科学技术文献出版社 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108635571A (en) * | 2018-07-19 | 2018-10-12 | 西安交通大学医学院第附属医院 | Irisin（irisin）Application in preventing and treating Severe Acute Pancreatitis SAP drug |
| CN113692445A (en) * | 2019-04-02 | 2021-11-23 | 巴伊沃爱普有限公司 | Recombinant irisin gene for optimizing expression in plants and method for producing recombinant irisin protein by using same |
| CN110101845A (en) * | 2019-05-24 | 2019-08-09 | 北京大学 | Application of the irisin in the drug that preparation prevention and treatment Postoperative Cognitive Dysfunction and blood-brain barrier are damaged mediated encephalopathy |
| CN110772528A (en) * | 2019-12-11 | 2020-02-11 | 吉林大学 | Application of iris polysaccharide in preparation of medicine for preventing and treating leptospirosis |
| CN110893233A (en) * | 2019-12-19 | 2020-03-20 | 川北医学院附属医院 | Application of irisin in preparation of anti-inflammatory drugs |
| CN111808186A (en) * | 2019-12-19 | 2020-10-23 | 山东大学第二医院 | Human-derived secretory FNDC5 protein and preparation method and application thereof |
| CN111808186B (en) * | 2019-12-19 | 2021-08-03 | 山东大学第二医院 | Human-derived secretory FNDC5 protein and preparation method and application thereof |
| WO2023184332A1 (en) * | 2022-03-31 | 2023-10-05 | 深圳先进技术研究院 | Ovary-targeting polypeptide and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107496908A (en) | Application of the irisin in anti-inflammatory drug is prepared | |
| Shukla et al. | In vitro and in vivo wound healing activity of asiaticoside isolated from Centella asiatica | |
| Cheng et al. | The healing effects of Centella extract and asiaticoside on acetic acid induced gastric ulcers in rats | |
| Yang et al. | Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy | |
| Bertolani et al. | The role of adipokines in liver fibrosis | |
| Sakai et al. | Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis | |
| Esmaili et al. | The multifaceted and controversial immunometabolic actions of adiponectin | |
| Zhang et al. | MCP-induced protein 1 attenuates sepsis-induced acute lung injury by modulating macrophage polarization via the JNK/c-Myc pathway | |
| Xu et al. | Water-soluble alkaloids extracted from Aconiti Radix lateralis praeparata protect against chronic heart failure in rats via a calcium signaling pathway | |
| Wang et al. | Polysaccharopeptide from Trametes versicolor blocks inflammatory osteoarthritis pain-morphine tolerance effects via activating cannabinoid type 2 receptor | |
| Jiang et al. | Nonphagocytic activation of NOX2 is implicated in progressive nonalcoholic steatohepatitis during aging | |
| Gao et al. | Interaction of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline with the angiotensin‐converting enzyme 2–angiotensin‐(1–7)–Mas axis attenuates pulmonary fibrosis in silicotic rats | |
| Kubo et al. | Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats | |
| Cui et al. | Minocycline attenuates oxidative and inflammatory injury in a intestinal perforation induced septic lung injury model via down-regulating lncRNA MALAT1 expression | |
| Fan et al. | DT-13 ameliorates TNF-α-induced nitric oxide production in the endothelium in vivo and in vitro | |
| Gao et al. | The mechanism underlying hypaconitine-mediated alleviation of pancreatitis–associated lung injury through up-regulating aquaporin-1/TNF-α | |
| Li et al. | YQWY decoction improves myocardial remodeling via activating the IL-10/Stat3 signaling pathway | |
| Huang et al. | Effect of electrical stimulation combined with diet therapy on insulin resistance via mTOR signaling | |
| CN111214660B (en) | Application of PAX4 gene expression inhibitor in preparation of medicine for inhibiting fibrosis | |
| CN106822864A (en) | A kind of method for suppressing the expression of proprotein convertases subtilisin 9 | |
| CN110694067A (en) | Application of substance for inhibiting angiopoietin-like protein8 | |
| Wu et al. | Compound xiebai capsule alleviates pulmonary vascular remodeling in monocrotaline-induced pulmonary arterial hypertension in rats | |
| Caughey et al. | Addison's disease with associated polyarthritis | |
| CN108704020A (en) | A kind of drug and preparation method thereof for treating leukoplakia vulvae | |
| Lang et al. | Loss of LEAP-2 alleviates obesity-induced myocardial injury by regulating macrophage polarization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171222 |
|
| RJ01 | Rejection of invention patent application after publication |